These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 7831376)

  • 21. Cost-effectiveness of rituximab (MabThera) in diffuse large B-cell lymphoma in The Netherlands.
    Groot MT; Lugtenburg PJ; Hornberger J; Huijgens PC; Uyl-de Groot CA
    Eur J Haematol; 2005 Mar; 74(3):194-202. PubMed ID: 15693788
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The cost-effectiveness of infliximab (Remicade) in the treatment of ankylosing spondylitis in Canada.
    Kobelt G; Andlin-Sobocki P; Maksymowych WP
    J Rheumatol; 2006 Apr; 33(4):732-40. PubMed ID: 16583476
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The economic impact of HA-1A (Centoxin) against endotoxin.
    Barriere SL
    Pharmacoeconomics; 1992 Nov; 2(5):408-13. PubMed ID: 10147053
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [A cost-efficacy analysis of treatment with antiendotoxin monoclonal antibodies in gram-negative sepsis].
    Badía X; Segú L; García Alonso F; Rovira J
    Med Clin (Barc); 1993 Jan; 100(3):84-9. PubMed ID: 8426499
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Immunotherapy using the anti-endotoxin antibody HA-1A (Centoxin) in patients with sepsis syndrome; fair results following protocol selection of patients].
    Costongs LG; Speelman P; van Lieshout JJ; van Deventer SJ; Lubbers MJ; Schipper HG
    Ned Tijdschr Geneeskd; 1993 Feb; 137(7):355-60. PubMed ID: 8437634
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An evaluation of the hemodynamic effects of HA-1A human monoclonal antibody.
    Kett DH; Quartin AA; Sprung CL; Fisher CJ; Peña MA; Heard SO; Zimmerman JL; Albertson TE; Panacek EA; Eidelman LA
    Crit Care Med; 1994 Aug; 22(8):1227-34. PubMed ID: 8045141
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [A cost-effectiveness analysis of treatment with antiendotoxin monoclonal antibodies in gram-negative sepsis].
    Tebas P
    Med Clin (Barc); 1993 Dec; 101(19):757-8. PubMed ID: 8289526
    [No Abstract]   [Full Text] [Related]  

  • 28. The HA-1A monoclonal antibody for gram-negative sepsis.
    N Engl J Med; 1991 Jul; 325(4):279-83. PubMed ID: 2057029
    [No Abstract]   [Full Text] [Related]  

  • 29. [Immunotherapy using the anti-endotoxin antibody HA-1A in patients with sepsis syndrome; good results in relation to treatment with placebo].
    Wortel CH; von der Möhlen MA; van Deventer SJ; Schipper HG; Lorijn RH; ten Cate JW
    Ned Tijdschr Geneeskd; 1993 Feb; 137(7):350-4. PubMed ID: 8437633
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The economic impact and cost-effectiveness of monoclonal antibody therapy for sepsis.
    Chalfin DB; Fein AM
    Clin Infect Dis; 1993 Nov; 17 Suppl 2():S520-4. PubMed ID: 8274619
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Criteria for use of antiendotoxin monoclonal antibodies (HA-1A and E5) in adult and pediatric inpatients.
    Shepherd MF
    Clin Pharm; 1992 Mar; 11(3):257-60. PubMed ID: 1611816
    [No Abstract]   [Full Text] [Related]  

  • 32. Introduction of new technology into critical care practice: a history of HA-1A human monoclonal antibody against endotoxin.
    Luce JM
    Crit Care Med; 1993 Aug; 21(8):1233-41. PubMed ID: 8339592
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human monoclonal antibodies in sepsis.
    de Koning J; Westendorp RG
    Neth J Med; 1991 Oct; 39(3-4):129-30. PubMed ID: 1791872
    [No Abstract]   [Full Text] [Related]  

  • 34. Influence of alterations in foregoing life-sustaining treatment practices on a clinical sepsis trial. The HA-1A Sepsis Study Group.
    Sprung CL; Eidelman LA; Pizov R; Fisher CJ; Ziegler EJ; Sadoff JC; Straube RC; McCloskey RV
    Crit Care Med; 1997 Mar; 25(3):383-7. PubMed ID: 9118650
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HA-1A in gram-negative sepsis.
    Jennings M
    Pharmacoeconomics; 1992 Sep; 2(3):248-9. PubMed ID: 10147118
    [No Abstract]   [Full Text] [Related]  

  • 36. [Monoclonal antibodies and gram-negative bacterial sepsis: is their use really justified?].
    Alsar MJ; Sánchez-Palacios M
    Med Clin (Barc); 1993 Sep; 101(7):278. PubMed ID: 7746010
    [No Abstract]   [Full Text] [Related]  

  • 37. Immunotherapy of gram-negative septicemia.
    van Deventer SJ
    Prog Clin Biol Res; 1991; 367():135-9. PubMed ID: 1924423
    [No Abstract]   [Full Text] [Related]  

  • 38. Initial evaluation of human monoclonal anti-lipid A antibody (HA-1A) in patients with sepsis syndrome.
    Fisher CJ; Zimmerman J; Khazaeli MB; Albertson TE; Dellinger RP; Panacek EA; Foulke GE; Dating C; Smith CR; LoBuglio AF
    Crit Care Med; 1990 Dec; 18(12):1311-5. PubMed ID: 2245602
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Once-daily aminoglycoside administration in gram-negative sepsis. Economic and practical aspects.
    Parker SE; Davey PG
    Pharmacoeconomics; 1995 May; 7(5):393-402. PubMed ID: 10155327
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is HA-1A cost-effective?
    Jennings M
    Pharmacoeconomics; 1993 Jan; 3(1):84-6. PubMed ID: 10147125
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.